API Supply AgreementApi Supply Agreement • January 25th, 2021 • Emmaus Life Sciences, Inc. • Pharmaceutical preparations • California
This Agreement (this “Agreement”), is made and entered into this _16__ day of 6_, 2017 (the “Effective Date”) by and between Emmaus Life Sciences, Inc., a Delaware corporation with offices at 21250 Hawthorne Blvd., Suite 800, Torrance, California 90503, the United States of America (hereinafter called "Manufacturer") and Telcon Inc., Korea corporation ("Supplier"), with offices at 684, Dongtangiheung-ro, Giheung-gu, Yongin-si, Gyeonggi-do.
Amendment for Distribution Agreement on June 15, 2017 between Emmaus Life Sciences Inc. and Telcon Inc.Distribution Agreement • January 25th, 2021 • Emmaus Life Sciences, Inc. • Pharmaceutical preparations
Emmaus Life Sciences Inc. and Telcon Inc. agree to amend or add to the following content in the Distribution Agreement on June 15, 2017.
EXHIBIT C FORM OF THIRD AMENDMENT TO OFFICE LEASE AGREEMENT THIRD AMENDMENT TO OFFICE LEASE AGREEMENTOffice Lease Agreement • January 25th, 2021 • Emmaus Life Sciences, Inc. • Pharmaceutical preparations
THIS THIRD AMENDMENT TO OFFICE LEASE AGREEMENT (this "Second Amendment") is made and entered into effective as of _September 10_, 2019__ (the "Effective Date"), by and between RREF II PACIFIC CENTER LLC, a Delaware limited liability company ("Landlord"), and EMMAUS LIFE SCIENCES, INC., a Delaware corporation ("Tenant").
CREDIT ACCESS AND LOAN AGREEMENT ________________Credit Access and Loan Agreement • January 25th, 2021 • Emmaus Life Sciences, Inc. • Pharmaceutical preparations • California
THIS CREDIT ACCESS AND LOAN AGREEMENT (this “Agreement”) is made and entered into on January 10, 2020 by and between Yutaka Niihara, M.D., M.P.H. (“Lender”) and Emmaus Life Sciences, Inc., a Delaware corporation (“Emmaus”), with reference to the following facts:
Distributor AgreementDistributor Agreement • January 25th, 2021 • Emmaus Life Sciences, Inc. • Pharmaceutical preparations • California
This Agreement (this “Agreement”), is made and entered into this _15_day of _6__, 2017 (the “Effective Date”) by and between Emmaus Life Sciences, Inc., a Delaware corporation with offices at 21250 Hawthorne Blvd., Suite 800, Torrance, California 90503, the United States of America (hereinafter called "Manufacturer") and Telcon Inc., Korea corporation ("Distributor"), with offices at 684, Dongtangiheung-ro, Giheung-gu, Yongin-si, Gyeonggi-do.
매도청구권(Call Option-콜옵션) 계약서 Right to Sell (Call Option) AgreementCall Option Agreement • January 25th, 2021 • Emmaus Life Sciences, Inc. • Pharmaceutical preparations
This “right to sell(Call Option) agreement” (hereinafter “this agreement”) is executed on September 28, 2020 between the following parties.
Raw Material Supply AgreementRaw Material Supply Agreement • January 25th, 2021 • Emmaus Life Sciences, Inc. • Pharmaceutical preparations
This Agreement (this “Agreement”), is made by and between Emmaus Life Sciences. Inc. (hereinafter called "Manufacturer") and Telcon Inc. ("Supplier") in order to clarify the contractual rights and obligations between the parties regarding the supply of pharmaceutical grade L-glutamine (“PGLG”).
ADDITIONAL AGREEMENTAdditional Agreement • January 25th, 2021 • Emmaus Life Sciences, Inc. • Pharmaceutical preparations
This ADDITIONAL AGREEMENT (this “Agreement”) is made as of July 2, 2018 by and among (1) Evercore Investment Holdings Co., Ltd. (formerly Telcon Holdings Co. Ltd., “Evercore”), a company with its place of business in the Republic of Korea (“Korea”), (2) Telcon RF Pharmaceutical Inc. (formerly Telcon Inc., “Telcon”), a company with its place of business in Korea and (3) Emmaus Life Sciences, Inc. (“Emmaus”), a company with its place of business in U.S.A.
Telcon RF Pharmaceutical, Inc. 15th Bearer-type Interest Purchase Agreement for Unsecured Private Equity Convertible Bonds Principal Amount: KRW 30,000,000,000 September 28, 2020 Issuer: Telcon RF Pharmaceutical, Inc. Emmaus Life Sciences, Inc....Convertible Bond Purchase Agreement • January 25th, 2021 • Emmaus Life Sciences, Inc. • Pharmaceutical preparations
Telcon RF Pharmaceutical Inc. (hereinafter referred to as the “issuer”) issues the 15th unsecured privately held convertible bond for a total of KRW 30 billion (KRW 30,000,000,000) upon the approval of the board of directors held on September 28, 2020 (hereinafter referred to as “the main convertible bond”). Emmaus Life Sciences Inc. (hereinafter referred to as the "purchaser") is the purchaser, and the agreement is as follows.
